Use the interactive table below for planning purposes. It will give you a high level understanding of how long it typically takes to gain approval in popular markets worldwide, along with the cost of doing so. While this information applies to 80% of situations, your device may take longer to approve or may require a larger investment than the ranges provided below. Updated December 2017.
Market![]() |
Device Class | Risk | TIME* from submission to approval | COST** of gaining regulatory approval | COMPLEXITY*** of registration process |
---|---|---|---|---|---|
Class I Non-Sterile | Low | < 1 month |
1
|
1
|
|
Class I Sterile | Low | < 1 month |
1
|
1
|
|
Class IIa | Moderate | < 1 month |
1
|
1
|
|
Class IIb | High | < 1 month |
1
|
1
|
|
Class III | High | < 1 month |
1
|
1
|
|
Australia | Class I Non-Sterile | Low | <1 month |
1
|
1
|
Australia | Class I Sterile | Low | 2-3 months |
1
|
1
|
Australia | Class IIa | Moderate | 2-3 months |
1
|
1
|
Australia | Class IIb | High | 2-3 months |
1
|
1
|
Australia | Class III | High | 7-14 months |
2
|
3
|
Brazil | Class I and II Cadastro | Low | 1-3 months |
2
|
3
|
Brazil | Class III Registro | High | 8-15 months |
4
|
5
|
Brazil | Class IV Registro | High | 8-15 months |
4
|
5
|
Canada | Class I | Low | 2-4 months |
2
|
2
|
Canada | Class II | Low | 1-2 months |
1
|
2
|
Canada | Class III | High | 4-5 months |
3
|
4
|
Canada | Class IV | High | 6-8 months |
4
|
5
|
China | Class I | Low | <1 month |
2
|
2
|
China | Class II | High | 12-20 months |
5
|
5
|
China | Class III | High | 12-22 months |
5
|
5
|
Colombia | Class I | Low | <1 month |
1
|
1
|
Colombia | Class IIa | Moderate | <1 month |
1
|
1
|
Colombia | Class IIb | High | 4-6 months |
1
|
2
|
Colombia | Class III | High | 4-6 months |
1
|
1
|
Costa Rica | Class I | Low | 2-4 months |
1
|
2
|
Costa Rica | Class II | Moderate | 2-4 months |
1
|
2
|
Costa Rica | Class III | Moderate | 2-4 months |
2
|
3
|
Costa Rica | Class IV | High | 2-4 months |
2
|
3
|
Egypt | Low Risk (Sterile) | Low | 4-6 months |
1
|
1
|
Egypt | Moderate Risk (Sterile) | Moderate | 4-6 months |
1
|
1
|
Egypt | High Risk (Sterile) | High | 4-6 months |
1
|
1
|
Europe | Class I Non-Sterile | Low | N/A |
1
|
1
|
Europe | Class I Sterile | Low | 3-5 months |
3
|
2
|
Europe | Class IIa | Moderate | 3-5 months |
3
|
3
|
Europe | Class IIb | High | 3-6 months |
4
|
3
|
Europe | Class III | High | 6-9 months |
4
|
4
|
Hong Kong | Class IV | High | 8-12 months |
3
|
2
|
Hong Kong | Class I | Low | Not applicable | No rating | No rating |
Hong Kong | Class II | Moderate | 8-12 months |
2
|
2
|
Hong Kong | Class III | High | 8-12 months |
2
|
2
|
India | Non-notified IVD | High | <1 month |
1
|
1
|
India | Notified Medical Device or IVD | High | 9-12 months |
3
|
3
|
Israel | High Risk | High | 1-6 months |
2
|
2
|
Israel | Low Risk | Low | 1-6 months |
2
|
2
|
Israel | Moderate Risk | Moderate | 1-6 months |
2
|
2
|
Japan | Class I - General | Low | <1 month |
2
|
2
|
Japan | Class II - Specified Controlled | Low | 3-5 months |
4
|
3
|
Japan | Class II - Controlled | Moderate | 7-9 months |
5
|
4
|
Japan | Class III - Highly Controlled | High | 9-11 months |
5
|
4
|
Japan | Class IV - Highly Controlled | High | 13-16 months |
5
|
5
|
Malaysia | Class A - Active/Sterile/Measuring | Low | 1-2 months |
2
|
3
|
Malaysia | Class B | Moderate | 3-4 months |
2
|
3
|
Malaysia | Class C | High | 6-7 months |
2
|
3
|
Malaysia | Class D | High | 7-8 months |
2
|
3
|
Mexico | Low Risk | Low | 1-3 months |
2
|
2
|
Mexico | Class I | Low | 3-10 months |
3
|
3
|
Mexico | Class II | High | 3-10 months |
3
|
3
|
Mexico | Class III | High | 3-10 months |
3
|
3
|
Russia | Class I | Low | 6-10 months |
4
|
4
|
Russia | Class IIa | Low | 8-12 months |
5
|
5
|
Russia | Class IIb | High | 8-12 months |
5
|
5
|
Russia | Class III | High | 8-12 months |
5
|
5
|
Saudi Arabia | Low Risk | Low | 1-6 months |
2
|
3
|
Saudi Arabia | Moderate Risk | Moderate | 1-6 months |
3
|
2
|
Saudi Arabia | High Risk | High | 1-6 months |
3
|
2
|
Singapore | Class A Non-Sterile | Low | Auto approval |
1
|
1
|
Singapore | Class A Sterile | Low | 1-2 months |
1
|
2
|
Singapore | Class B | Moderate | 1-4 months |
2
|
2
|
Singapore | Class C | High | 4-6 months |
2
|
3
|
Singapore | Class D | High | 6-8 months |
3
|
3
|
South Korea | Class I | Low | <1 month |
2
|
1
|
South Korea | Class II | Moderate | 4-6 months |
4
|
4
|
South Korea | Class III | High | 6-10 months |
4
|
4
|
South Korea | Class IV | High | 6-10 months |
4
|
4
|
Taiwan | Class I | Low | 1 - 2 months |
2
|
2
|
Taiwan | Class II | Moderate | 10-12 months |
3
|
2
|
Taiwan | Class III | High | 10-12 months |
3
|
3
|
United States | Class II | Moderate | 6-9 months |
3
|
4
|
United States | Class III | High | 18-30 months |
5
|
5
|
United States | Class I | Low | <1 month |
1
|
2
|
* The time frames shown above are typical for the majority of medical device submissions but assume that your device does not contain animal tissue, medicinal substances or employ entirely novel technology. Your length of approval will depend on the quality and completeness of your technical documentation and how much time you take to address additional information requests from authorities after submission. YOUR SUBMISSION(S) MAY TAKE MORE TIME THAN WHAT IS SHOWN ABOVE.
** Estimated costs includes registration application fees, product testing, in-country representation, submission preparation consulting and translation of documents. Does not include cost of implementing or auditing a quality management system compliant with ISO 13485 or US FDA 21 CFR Part 820, if applicable. LOW = Less than US$5000; LOW/MODERATE = US$5000-$15000; MODERATE = US$15000-$30000; MODERATE/HIGH = US$30000-$50000; HIGH = US$50000 or more.
*** Our rating of the complexity of the registration process is based on Emergo’s experience with thousands of submissions and the opinion of nearly 1,000 QA/RA professionals worldwide who were asked to rate the difficulty of registering a device in each country. The European CE Marking process is generally considered the mid-point to which all other markets are compared.